Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | HTR2B | P41595 | 7/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310141 | 0.80 | DRD3 (0.49) | DRD3KCNH2HRH1HTR2CHTR2A | |
| SCHEMBL4872352 | 0.76 | HTR2C (0.46) | DRD3KCNH2HTR2CHTR2AHTR2B | |
| SCHEMBL2283767 | 0.72 | DRD3 (0.46) | DRD3KCNH2HRH1HTR2CHTR2A | |
| SCHEMBL4877007 | 0.70 | HTR2B (0.43) | DRD3KCNH2HRH1HTR2CHTR2A | |
| SCHEMBL4871755 | 0.67 | HTR2A (0.43) | DRD3KCNH2HRH1HTR2CHTR2A | |
| SCHEMBL4871914 | 0.65 | HTR2A (0.41) | DRD3KCNH2HRH1HTR2CHTR2A | |
| SCHEMBL12433774 | 0.60 | NPC1 (0.46) | HTR2CHTR2AHTR2B | |
| SCHEMBL24687752 | 0.59 | STAT3 (0.40) | DRD3KCNH2 | |
| SCHEMBL12439655 | 0.59 | DRD3 (0.40) | DRD3KCNH2HRH1 | |
| SCHEMBL2208510 | 0.59 | HTR2A (0.48) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | DRD3, SLC6A3, DRD2 | DRD3 1/4885KCNH2 686/4885HRH1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.